Description

Actilize (Alteplase) 50 mg. vial №1

Ingredients

Active ingredient: Alteplase
Other ingredients: Mannitol, Arginine, Phosphoric acid

Dosage

Dosage: The recommended dose of Actilize (Alteplase) is determined based on the patient’s weight and the condition being treated. It is administered intravenously under medical supervision.

Indications

Indications: Actilize (Alteplase) is indicated for the treatment of acute ischemic stroke, acute myocardial infarction, and pulmonary embolism.

Contraindications

Contraindications: Actilize (Alteplase) is contraindicated in patients with active internal bleeding, recent trauma or surgery, history of stroke within the past 3 months, and severe uncontrolled hypertension.

Directions

Directions: Actilize (Alteplase) should be administered by healthcare professionals trained in thrombolytic therapy. The vial should be reconstituted according to the package insert instructions before use.

Scientific Evidence

Actilize (Alteplase) has been extensively studied in clinical trials for its efficacy in thrombolytic therapy. Research published in the New England Journal of Medicine has shown that Alteplase significantly improves outcomes in patients with acute ischemic stroke when administered within the recommended time window.

Additional Information

Actilize (Alteplase) acts by converting plasminogen to plasmin, which helps dissolve blood clots. This pharmacological action makes it a crucial intervention in the management of acute thrombotic events. Compared to other thrombolytic agents, Alteplase has shown superior efficacy and safety profiles in various studies.

Actilize (Alteplase) is a life-saving medication that plays a vital role in the management of acute thrombotic conditions. Its proven efficacy and safety profile make it a preferred choice in emergency settings. Healthcare providers should be well-versed in the proper administration and monitoring of patients receiving Alteplase to ensure optimal outcomes.